On November 16, 2018, Jeffrey Hackman notified Novelion Therapeutics Inc. that he would be resigning as the company's Interim Chief Executive Officer and Chief Operating Officer. Mr. Hackman's resignation took effect on November 19, 2018. On November 19, 2018, the company's Board of Directors appointed Benjamin Harshbarger, the company's General Counsel, to serve as the company's Interim Chief Executive Officer (and its principal executive officer), effectively immediately.